Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levonidazole is a nitroimidazole antimicrobial agent structurally related to metronidazole. It is primarily developed and used in China for the treatment of infections caused by anaerobic bacteria and certain protozoa. Like other nitroimidazoles, levonidazole acts by entering susceptible microorganisms and undergoing reduction to generate reactive intermediates that damage microbial DNA, leading to cell death. Levonidazole has been investigated as an alternative to metronidazole with potentially improved pharmacokinetic properties and tolerability profile. Its main indications are similar to those of metronidazole, including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and other anaerobic or mixed bacterial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levonidazole.